The PMWC 2023 Luminary Award recognizes the recent contributions of prominent figures who have accelerated Precision Medicine into the clinic. The PMWC 2023 honoree is Dr. Kelly Caudle, the Co-PI and Director of the Clinical Pharmacogenetics Implementation Consortium (CPIC®) an international consortium of volunteers and a small, dedicated staff who are interested in facilitating the use of pharmacogenetic tests results for better patient care.
The Pioneer Award is given to a venerable individual whose foresight and groundbreaking contributions to Precision Medicine propelled the movement in earlier years, allowing it to gain momentum to evolve into the standard of care that it is becoming today. The 2023 PMWC Pioneer honoree is Dr. Dan M. Roden, who imagined a large-scale biobank integrated with electronic health records to help doctors “personalize” medical care for their patients. That vision became BioVU, today one of the world’s largest bio-banks, with around 350,000 DNA samples from a single health care system.
Santa Clara Convention Center
*After more than a decade of hosting the Award reception the night before the main PMWC conference, this year the PMWC Award Ceremonies will be held at the kick-off of each day of the program. All attendees may take part without an RSVP.
Santa Clara Convention Center
Exhibition Halls A-D
5001 Great America Pkwy
Santa Clara, CA 95054
1,500 on-site parking spaces in a 3-story adjacent parking garage (directions) on the Santa Clara Convention Center campus shared with the Hyatt Regency and TechMart. Additional overflow parking may be available in surrounding lots based on availability as well as the City of Santa Clara Garage (directions) across the street.
FROM SAN JOSE INTERNATIONAL AIRPORT – 5.4 MILES
Take San Jose International Airport’s Guadalupe Pkwy. Exit. Turn left on Guadalupe Pkwy. Follow onto I-101 North. Follow I-101 North roughly three miles and exit at Great America Pkwy. Turn right onto Great America Pkwy. The Silicon Valley Convention Center is located at Great America Pkwy. and Tasman Ave. You can find the Convention Center Parking Garage by exiting at the Hyatt Regency’s 2nd driveway at Bunker Hill Rd.
FROM SAN FRANCISCO INTERNATIONAL AIRPORT – 31 MILES
Follow San Francisco International Airport’s exit signs to I-101 South towards San Jose. Take I-101 South roughly 30-40 minutes and exit at Great America Pkwy. Turn left at Great America Pkwy. The Convention Center is at Great America Pkwy. and Tasman Ave. You can find the Silicon Valley Convention Center Parking Garage by exiting Great America Pkwy. at the Hyatt Regency’s 2nd driveway at Bunker Hill Rd.
FROM OAKLAND INTERNATIONAL AIRPORT –33.1 MILES
Exit Oakland International Airport and take Hegenberger Rd. to I-880 South towards San Jose. Take I-880 roughly 30-40 minutes to Highway 237 towards Mountain View. Follow Highway 237 to Great America Pkwy. Exit. Turn left on Great America Pkwy. The Convention Center is at Great America Pkwy. and Tasman Ave. You can find the Convention Center Parking Garage by exiting off Great America Pkwy. at the Hyatt Regency’s 2nd driveway at Bunker Hill Rd.
The PMWC Luminary Award recognizes recent contributions of preeminent figures who have accelerated personalized medicine into the clinic.
Led a coronavirus vaccine and antiviral drug development in record time
Oversaw R&D of the first antiviral synthetic mRNA vaccines ever created as well as the one against COVID-19
Leader in neonatal molecular diagnosis using rapid Whole Genome Sequencing™
Oversaw clinical development and global approval of the 2nd mRNA COVID-19 vaccine
Relentless crusader against some of humanity’s most virulent medical threats
Early leader in pharmacogenomics discovery research and its clinical implementation
Co-developer of one of the leading COVID-19 vaccines
Co-developer of one of the leading COVID-19 vaccines
Leader and visionary entrepreneur in precision genomic diagnostics
Discoveries led to adoptive immunotherapy with genetically engineered T cells
Neurobiologist who led the development of optogenetics and CRISPR
Incited the movement to build systems for individuals to access and share health data
Developed CAR-T therapy, the world’s first gene-based cancer therapy
Pioneered the CRISPR-CAS9 Genome Editing Technology
Pioneered Cancer Immunotherapy Through Discovery of the Immune Checkpoint Blockade
Pioneered the Groundbreaking Crispr-Cas9 Genome Editing Technology
Pioneer in Human Brain Circuit Mapping to Advance Precision Neuropathology
Expedited Development of Groundbreaking Therapies
Breast Cancer Treatment Paradigm Shifter
Developed R-loop Technique of Electron Microscopy
Established Illumina as the leader in sequence technology
FDA Director, fast-tracked targeted drugs through FDA approval
Co-inventor, blockbuster drug, Gleevec
Contributions to the sequencing of genomes and interpreting such data; In Neuroscience he established a “functional connectome”
Inventions included the automated DNA sequencer and a tool for synthesizing DNA
Pioneered the study of gut microbial ecology and evolution and today addresses the global challenges of obesity and undernutrition
Advancing Precision Medicine by Leading Sequencing of the Human Genome and Other Major Government Initiatives
Sequencing Technologies Visionary and Leader in Genomics and Cancer Genomics
Conception, Implementation and Advocacy for Precision Medicine
Pioneered and advocate for pharmacogenomic personalized medicine
Developing innovative data science methods to improve patient care through mobile health in chronic disease
Pioneered genetics and genomics in cardiovascular medicine and led the era of wireless medicine
The PMWC Pioneer Award is given to a venerable individual whose foresight and groundbreaking contributions to Precision Medicine propelled the movement in its early years, allowing it to gain momentum to evolve into the standard of care that it is becoming today.
Developed newborn screening test for severe combined immunodeficiency
Co-developed synthetic mRNA technology enabling the first two FDA-approved COVID-19 vaccines
Enabled precision medicine through the venture backing of companies that entered the field early and through his mentorship of their founders
Developed Foundational Technologies Designed to Invent Groundbreaking Therapies
Pioneered the concept of antibodies being used as personalized anticancer drugs
Leading Genetic and Genomic Research Initiatives that Enable Precision Medicine in the UK and Globally
Co-discovered the BRCA2 gene mutation and made discoveries leading to PARP inhibition in breast and other cancers
Steve Quake has pioneered innovative approaches to biological measurement
Pioneer in Regenerative Medicine & Cancer Stem Cells
Widely recognized as “Father of Personalized Medicine”
1st Draft Human Gen., 1st Complete Diploid Human Gen., and 1st Synth. Bact. Cell
Discovered That An Unborn Fetus Releases Fetal DNA Into Maternal Plasma
The first to establish that a single DNA mutation could lead to a human disease, and the first to diagnose a human disease by using DNA
Pioneered large-scale studies identifying genetic risk in diabetes and Bipolar Disorder
Pioneer in Business Leadership to Advance Life-Saving Therapies and Institutional Collaboration
Advances Personalized Medicine Through His Business, Science and Policy Acumen
Developer, First Predictive Test for Huntington’s Disease
Launched both earliest genetically-targeted therapy and molecular diagnostic assay
The PMWC Most Promising Company Competition has accompanied PMWC since 2009 with the goal to assist “rising star” startups in Diagnostics, Therapeutics, and Health Tech to increase their visibility, provide them with a platform to present to a group of leading investors, as well as to potential clients and partners so they can succeed on their path forward.
Abreos Biosciences is a precision medicine company in San Diego, CA developing laboratory-based and near-patient tests for precision dosing of biologic drugs. Abreos has cultivated a diverse portfolio of Veritope™ tests that allow for direct monitoring of blood concentrations of monoclonal antibody drugs (novel or biosimilar). Website: abreos.com
Two Pore Guys created a solid-state nanopore-based diagnostic testing platform that can detect nucleic acids, proteins and other analytes with comparable performance of lab equipment, in a glucometer-style system. Website: twoporeguys.com
Every patient’s tumor is molecularly unique – Gritstone Oncology deploys a proprietary tumor antigen prediction model based upon patient tumor sequencing/mass spectrometry to deliver antigens as personalized therapeutic vaccine alongside checkpoint inhibitors. Website: gritstoneoncology.com
HealthMyne is an imaging informatics company dedicated to transforming patient care by enabling image data mining within the clinical workflow. Built on an FDA-cleared diagnostic platform, HealthMyne tools will increase radiologist efficiency by automating both data capture and structured reports. Website: healthmyne.com
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Website: insilicomedicine.com
AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests at any time and any place. The patented pScreen™ platform technology employs a single-use blood test the size of a credit card in tandem with a smartphone application to quickly detect disease-specific biomarker levels. Website: acceldx.com
T2 Biosystems is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. Their new class of clinical diagnostics powered by T2MR is the world’s first direct detection technology that delivers superior sensitivity at unmatched speed to guide more effective clinical decision-making. IPO, Aug. 2014. Website: t2biosystems.com
ElMindA has developed the BNA™ technology platform, which for the first time allows high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain at work, capturing information on the composition, connectivity, synchronization and operation of brain networks. Website: elminda.com
Horizon Discovery Limited has developed a translational genomics platform and drug discovery toolbox that enables the development of new therapies targeted at the genetic features that drive an individual’s cancer. IPO, March 2014. Website: horizondiscovery.com
QuantaLife provides advanced genetic analysis systems for research. QuantaLife has commercialized the Droplet Digital™ (ddPCR) system, the most accurate genetic analysis platform available today. The system is the first cost-effective, high-resolution platform available for the validation of next-generation sequencing discoveries. With the ddPCR system, researchers can explore complex genetic landscapes in high-definition, discover new disease associations, and define a new category of improved molecular diagnostic tests. Acquired by Bio-Rad, October 2011. Website: bio-rad.com
Applied Immune Technologies’ (AIT) core technology platforms encompass the identification and validation of novel MHC-based targets, as well as development of therapeutic Human Recombinant T-Cell Receptor-Like (TCRL) antibodies with the unique ability to bind with these intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells. Acquired by Adicet Bio, January 2016.Website: tcrl.co.il
Boston Heart Diagnostics is a heart health management company providing integrated diagnostic and patient management solutions that are advancing cardiovascular disease risk assessment, monitoring and treatment. The Company’s goal is to predict, prevent, manage and reverse cardiovascular disease by improving patient assessment and management. Acquired by Eurofins Scientific, December 2014. Website: bostonheartdiagnostics.com